Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated – chatter @ #wallstreetbets

0
193

Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated
https://www.globenewswire.com/news-release/2021/06/09/2244416/0/en/Atossa-Therapeutics-Announces-Final-Data-from-Phase-2-Endoxifen-Breast-Cancer-Study-Primary-Endpoint-Met-65-1-Reduction-in-Biomarker-Ki-67-Secondary-Endpoint-Met-Endoxifen-Safe-and.html

This site uses Akismet to reduce spam. Learn how your comment data is processed.